Symptoms of overdose include clumsiness or unsteadiness, coma, dizziness (severe), drowsiness (severe), nausea (severe), and problems with vision.
An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378)
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ceritinib | Trimethadione may increase the bradycardic activities of Ceritinib. |
| Ivabradine | Trimethadione may increase the bradycardic activities of Ivabradine. |
| Ruxolitinib | Ruxolitinib may increase the bradycardic activities of Trimethadione. |
| Buprenorphine | Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trimethadione. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Trimethadione. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Trimethadione. |
| Hydrocodone | Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Trimethadione can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Trimethadione may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Trimethadione. |
| Mirtazapine | Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Trimethadione. |
| Orphenadrine | Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Trimethadione. |
| Pramipexole | Trimethadione may increase the sedative activities of Pramipexole. |
| Ropinirole | Trimethadione may increase the sedative activities of Ropinirole. |
| Rotigotine | Trimethadione may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Trimethadione. |
| Sodium oxybate | Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Trimethadione. |
| Thalidomide | Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Dabrafenib | The serum concentration of Trimethadione can be decreased when it is combined with Dabrafenib. |
| Luliconazole | The serum concentration of Trimethadione can be increased when it is combined with Luliconazole. |
| Mefloquine | The therapeutic efficacy of Trimethadione can be decreased when used in combination with Mefloquine. |
| Mianserin | The therapeutic efficacy of Trimethadione can be decreased when used in combination with Mianserin. |
| Orlistat | Orlistat can cause a decrease in the absorption of Trimethadione resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Topotecan | Trimethadione may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy. |
| Cimetidine | The serum concentration of Trimethadione can be increased when it is combined with Cimetidine. |
| Clopidogrel | The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Trimethadione. |
| Efavirenz | The serum concentration of Trimethadione can be decreased when it is combined with Efavirenz. |
| Melatonin | The therapeutic efficacy of Trimethadione can be decreased when used in combination with Melatonin. |
| Nafcillin | The therapeutic efficacy of Trimethadione can be decreased when used in combination with Nafcillin. |
| Nitroprusside | Trimethadione may increase the hypotensive activities of Nitroprusside. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Trimethadione. |
| Dantrolene | The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Trimethadione. |
| Lithium citrate | The risk or severity of adverse effects can be increased when Trimethadione is combined with Lithium citrate. |
| Lithium carbonate | The risk or severity of adverse effects can be increased when Trimethadione is combined with Lithium carbonate. |
| Lithium hydroxide | The risk or severity of adverse effects can be increased when Trimethadione is combined with Lithium hydroxide. |
| Mifepristone | The serum concentration of Trimethadione can be increased when it is combined with Mifepristone. |
| Tetracosactide | The risk or severity of liver damage can be increased when Tetracosactide is combined with Trimethadione. |
| Boceprevir | The serum concentration of Trimethadione can be increased when it is combined with Boceprevir. |
| Ethanol | Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Trimethadione. |
| Duloxetine | The risk or severity of adverse effects can be increased when Trimethadione is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Trimethadione is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Trimethadione is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Trimethadione is combined with Sibutramine. |
| Zimelidine | The risk or severity of adverse effects can be increased when Trimethadione is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Trimethadione is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Trimethadione is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Trimethadione is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Trimethadione is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when Trimethadione is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Trimethadione is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Trimethadione is combined with Alaproclate. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Citalopram. |
| Escitalopram | The risk or severity of adverse effects can be increased when Trimethadione is combined with Escitalopram. |
| Lumacaftor | The serum concentration of Trimethadione can be decreased when it is combined with Lumacaftor. |
| Carteolol | Trimethadione may increase the arrhythmogenic activities of Carteolol. |
| Tocainide | Trimethadione may increase the arrhythmogenic activities of Tocainide. |
| Metipranolol | Trimethadione may increase the arrhythmogenic activities of Metipranolol. |
| Aprindine | Trimethadione may increase the arrhythmogenic activities of Aprindine. |
| Xylometazoline | Trimethadione may increase the arrhythmogenic activities of Xylometazoline. |
| Sparteine | Trimethadione may increase the arrhythmogenic activities of Sparteine. |
| Fasudil | Trimethadione may increase the arrhythmogenic activities of Fasudil. |
| Spiradoline | Trimethadione may increase the arrhythmogenic activities of Spiradoline. |
| Tiracizine | Trimethadione may increase the arrhythmogenic activities of Tiracizine. |
| Ethacizine | Trimethadione may increase the arrhythmogenic activities of Ethacizine. |
| Hydroquinine | Trimethadione may increase the arrhythmogenic activities of Hydroquinine. |
| Bioallethrin | Trimethadione may increase the arrhythmogenic activities of Bioallethrin. |
| Fosfructose | Trimethadione may increase the arrhythmogenic activities of Fosfructose. |
| Hydroquinidine | Trimethadione may increase the arrhythmogenic activities of Hydroquinidine. |
| SOR-C13 | Trimethadione may increase the arrhythmogenic activities of SOR-C13. |
| Digoxin | Trimethadione may increase the arrhythmogenic activities of Digoxin. |
| Acetyldigitoxin | Trimethadione may increase the arrhythmogenic activities of Acetyldigitoxin. |
| Deslanoside | Trimethadione may increase the arrhythmogenic activities of Deslanoside. |
| Cymarin | Trimethadione may increase the arrhythmogenic activities of Cymarin. |
| Metildigoxin | Trimethadione may increase the arrhythmogenic activities of Metildigoxin. |
| Acetyldigoxin | Trimethadione may increase the arrhythmogenic activities of Acetyldigoxin. |
| Hyoscyamine | Trimethadione may increase the arrhythmogenic activities of Hyoscyamine. |
| Niguldipine | Trimethadione may increase the arrhythmogenic activities of Niguldipine. |
| Diltiazem | Diltiazem may increase the arrhythmogenic activities of Trimethadione. |
| Nimodipine | Trimethadione may increase the arrhythmogenic activities of Nimodipine. |
| Cinnarizine | Trimethadione may increase the arrhythmogenic activities of Cinnarizine. |
| Atropine | Trimethadione may increase the arrhythmogenic activities of Atropine. |
| Adenosine | Trimethadione may increase the arrhythmogenic activities of Adenosine. |
| Levosimendan | Trimethadione may increase the arrhythmogenic activities of Levosimendan. |
| Flecainide | Trimethadione may increase the arrhythmogenic activities of Flecainide. |
| Prenylamine | Trimethadione may increase the arrhythmogenic activities of Prenylamine. |
| Fluspirilene | Trimethadione may increase the arrhythmogenic activities of Fluspirilene. |
| Azimilide | Trimethadione may increase the arrhythmogenic activities of Azimilide. |
| Tedisamil | Trimethadione may increase the arrhythmogenic activities of Tedisamil. |
| Fendiline | Trimethadione may increase the arrhythmogenic activities of Fendiline. |
| Benidipine | Trimethadione may increase the arrhythmogenic activities of Benidipine. |